Victoria Stern

The FDA continues to approve new drugs and expand indications for others at a rapid pace. Here’s a summary of what happened last month.

In a real-world population of patients with EGFR-mutant advanced lung cancer, overall survival was much worse in patients who would not have been eligible for the pivotal FLAURA trial.

GPT-4 provided highly accurate pancreatic ductal adenocarcinoma synoptic reports from original reports and outperformed GPT-3.5.

Oncologist Rebecca Shatsky, MD, yelled at an insurance company physician during a peer-to-peer when he refused to approve a drug for her patient. Her office gave her a standing ovation.

This new column will explore the ways in which insurance companies may dictate or restrict cancer care. Each month, oncologists and patients will share their experiences. But first, how did we get here?

Experts remain divided on the value of discarded cancer drugs but agree that ‘we all are chipping away at this monster of cancer care costs.’

Many individuals who are eligible for lung cancer screening have limited or no access to a facility that conducts such screening, not only in rural areas, but also in urban areas.

Many individuals who are eligible for lung cancer screening have limited or no access to a facility that conducts such screening, not only in rural areas, but also in urban areas.

Although COVID-19 cases in the US have declined recently, demand for COVID-19 treatments continues to outstrip supply, leaving many oncologists with a difficult decision about who receives care.

Experts highlight how they are building on the recent therapeutic advances in HER2-positive MBC and how new options have begun to reshape the treatment landscape for patients.